Aarti Drugs Ltd 04 Nov 2026 12:00 AM
Aarti Drugs Ltd consolidated sales up 17.57% on year in Q3FY2026, net profit soared by 65.11%,
Aarti Drugs Ltd share price gained 2.60% to Rs 465.6 after the company`s net profit saw a strong growth of 65.11% to Rs 82.77 crore, while revenue from operations increased 17.57% to Rs 826.24 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.73 lakh crore, rising 5.41%. It has improved by 1.84% over last one week and gained upto 1.37% in last one month while the market capitalization of Aarti Drugs Ltd has marginally improved by 4% and 13.30% in the same period respectively. Profit before tax (PBT) of Aarti Drugs Ltd stood at Rs 109.28 crore in Q3 FY26, jumping 80.90% year-on-year, and surging by 57.83% quarter-on-quarter. EBITDA came in at Rs 133 crore, rallying 57.75% YoY and expanding by 36.37% sequentially. Total expenses increased by 13.94% to Rs 709.88 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 477.33 crore, posting a minor increase of 1.70% YoY, while employee benefits expense was at Rs 37.13 crore, ticking higher by 1.70% YoY. For the TTM ended FY26, revenue from operations inched higher 7.47% to Rs 2565.31 crore, while net profit rose by 15.97% to Rs 194.94 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 28089% to Rs 306.8 crore, and PBT softened 0.41% to Rs 210.9 crore compared to previous TTM. The company`s consolidated net cash flow from operating activities stood at Rs 253.54 crore in FY26, as against Rs 244.58 crore in FY25. Aarti Drugs Ltd retreated by 7.39% in last one year, outperforming the benchmark BSE Sensex which has slipped by 8.41% during the same period.
Aarti Drugs Ltd 07 Oct 2026 12:00 AM
Aarti Drugs reported securities dematerialization processing confirmation from MUFG Intime India,
Aarti Drugs Limited informed the BSE and National Stock Exchange that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, confirmed the receipt and processing of securities for dematerialization during the quarter ended September 30, 2026, in accordance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.
Aarti Drugs Ltd 29 Sep 2026 12:00 AM
Aarti Drugs will halt trading ahead of financial results declaration in late September,
Aarti Drugs Limited will close its trading window from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026, as per SEBI (Prohibition of Insider Trading) Regulations, 2015, the company said in a filing to the BSE Limited and National Stock Exchange of India Limited.
Aarti Drugs Ltd 25 Aug 2026 12:00 AM
Aarti Drugs to convene board meeting August 27th to approve a stock option plan,
Aarti Drugs Limited will hold a board meeting on Thursday, August 27, 2026, to consider and approve the “Aarti Drugs Limited – Performance Stock Option Plan 2026,” and the trading window for the company will be closed from August 25, 2026, until August 29, 2026, in accordance with SEBI regulations.
Aarti Drugs Ltd 01 Aug 2026 12:00 AM
Aarti Drugs consolidated net profit declines 6.94% in the June 2026 quarter,
Net profit of Aarti Drugs declined 6.94% to Rs 50.17 crore in the quarter ended June 2026 as against Rs 53.91 crore during the previous quarter ended June 2025. Sales rose 19.01% to Rs 702.78 crore in the quarter ended June 2026 as against Rs 590.51 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales702.78590.51 19 OPM %13.9712.55 - PBDT89.7965.83 36 PBT71.3351.11 40 NP50.1753.91 -7 Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now